Alternative Drug Delivery Market Study Discussed On AudioInvestor.Com.

DALLAS--(BUSINESS WIRE)--Sept. 23, 1999--

The alternative drug delivery market is a growth segment of the pharmaceutical industry according to a three month, five hundred page study recently released by Front Line Strategic Management Consultants, Inc.

Hau-Chau Tran, an author of the study, notes that alternative drug delivery technology can extend the patent life of existing drugs, which makes these technologies very attractive to drug companies. She also notes that alternative drug delivery technology can significantly improve the performance of existing drugs, and differentiate a company's product in the competitive marketplace.

Drug delivery companies are generally exposed to less risk than biotechnology companies according to Tran as they generally focus on drugs that have already been approved by the FDA once. As such they may not have to prepare some of the extensive studies that would be required with a new drug. The development period, and hence the period to market, is therefore much shorter.

In a recent interview Tran discusses the drug delivery market, delivery alternatives, technical developments, and the following companies: Ethical Holdings (Nasdaq:ETHCY), Alza (NYSE:AZA), Noven (Nasdaq:NOVN), Cygnus (Nasdaq:CYGN), Nastech (Nasdaq:NSTK), The Liposome Company (Nasdaq:LIPO), and Gilead Sciences (Nasdaq:GILD).

The Hau-ChauTran interview is now available for replay at AudioInvestor.Com Web site. To listen, investors should go to http://www.theaudioinvestor.com.

AudioInvestor.Com is an Internet educational broadcasting company carrying interviews on economic, investment, legal, and managerial issues, and with its media partners helps organizations deliver their message to a worldwide audience.